How Relevant Is Treatment-Related Infertility for Individual Treatment Selection in Hodgkin Lymphoma?

Affiliations

Comment

Clemens F Hess et al. J Clin Oncol. 2017.

. 2017 Jan 20;35(3):372.

doi: 10.1200/JCO.2016.69.6575. Epub 2016 Oct 28.

¹ Clemens F. Hess and Markus A. Schirmer, University Medical Center Göttingen, Göttingen, Germany.

No abstract available

Comment in

Reply to C.F. Hess et al.
Carde PP, Grynberg M, Poirot C, Glimelius B, Mounier N. Carde PP, et al. J Clin Oncol. 2017 Jan 20;35(3):374. doi: 10.1200/JCO.2016.69.7995. Epub 2016 Oct 28. J Clin Oncol. 2017. PMID: 28095265 No abstract available.
Reply to H.J.A. Adams et al, E.A. Hawkes et al, and C.F. Hess et al.
Borchmann P, Engert A. Borchmann P, et al. J Clin Oncol. 2017 Jan 20;35(3):375-376. doi: 10.1200/JCO.2016.69.7987. Epub 2016 Oct 28. J Clin Oncol. 2017. PMID: 28095272 No abstract available.

Balancing the Risk-Benefit Ratio in the Treatment of Patients With Advanced-Stage Hodgkin Lymphoma.
Borchmann P, Engert A. Borchmann P, et al. J Clin Oncol. 2016 Jun 10;34(17):1975-7. doi: 10.1200/JCO.2015.66.3823. Epub 2016 Apr 11. J Clin Oncol. 2016. PMID: 27069072 No abstract available.
Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. Carde P, et al. J Clin Oncol. 2016 Jun 10;34(17):2028-36. doi: 10.1200/JCO.2015.64.5648. Epub 2016 Apr 25. J Clin Oncol. 2016. PMID: 27114593 Clinical Trial.